← Back to Search

Monoclonal Antibodies

Dupilumab for Allergic Contact Dermatitis

Phase 4

Recruiting

Research Sponsored by Brigham and Women's Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up week 0, week0+72-120 hours, week 12 and week 12+72-120 hours

Awards & highlights

Study Summary

This trial will test whether the drug dupilumab can help improve symptoms in people with allergic contact dermatitis.

Eligible Conditions

Allergic Contact Dermatitis

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ week 0, week0+72-120 hours, week 12 and week 12+72-120 hours

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~week 0, week0+72-120 hours, week 12 and week 12+72-120 hours

This trial's timeline: 3 weeks for screening, Varies for treatment, and week 0, week0+72-120 hours, week 12 and week 12+72-120 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in Investigator's Global Assessment (IGA) score

Secondary outcome measures

Blood Samples

Change in Body Surface Area (BSA)

Change in Dermatology Life Quality Index (DLQI)

+4 more

Side effects data

From 2021 Phase 4 trial • 188 Patients • NCT04033367

Conjunctivitis

Headache

Dermatitis Atopic

Nasopharyngitis

Accidental Overdose

Drug Hypersensitivity

Polyarthritis

100%

80%

60%

40%

20%

Study treatment Arm

OLE Period: Placebo/Dupilumab

DB Period: Placebo

DB Period: Dupilumab

OLE Period: Dupilumab/Dupilumab

Trial Design

1Treatment groups

Experimental Treatment

Group I: Subjects with Allergic Contact DermatitisExperimental Treatment1 Intervention

Dupilumab 600 mg/4 mL subcutaneously once, then 300 mg/2 mL every 2 weeks for 10 weeks

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Dupilumab

FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Brigham and Women's HospitalLead Sponsor

1,609 Previous Clinical Trials

11,470,297 Total Patients Enrolled

Regeneron PharmaceuticalsIndustry Sponsor

615 Previous Clinical Trials

379,817 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What primary purpose does Dupilumab serve in medical treatment?

"Dupilumab may be a viable treatment for those suffering from dermatitis, atopic illness, corticosteroid resistance, and eosinophilia."

Answered by AI

To what extent is this trial being embraced by prospective test subjects?

"Affirmative. Information on clinicaltrials.gov indicates that this research trial is still actively recruiting participants, with an initial posting date of December 18th 2019 and a recent update on October 12th 2021. The investigation requires 20 volunteers at one medical site to complete the study."

Answered by AI

What prior research has been conducted using Dupilumab as a treatment option?

"As of this moment, Dupilumab is being studied in 49 separate clinical trials. Of those studies, 13 are currently in the 3rd phase. Even though a majority of them take place near Palo Alto California, worldwide there are 2603 locations recruiting participants for these experiments."

Answered by AI

Is this trial an original experiment or does it draw inspiration from prior studies?

"Currently, 49 clinical trials for Dupilumab are ongoing across 436 cities and 43 countries. Sanofi first sponsored an 880-person trial of this drug in 2015 which reached its Phase 3 approval stage before concluding. Since that time, 54 additional studies have been finalized."

Answered by AI

Is there still availability to join this experiment?

"Affirmative, clinicaltrials.gov confirms that this scientific investigation is actively recruiting subjects as of October 12th 2021. The trial was initially posted on December 18th 2019 and seeks 20 individuals across a single centre."

Answered by AI